CTOs on the Move

Apeel Sciences

www.Apeel.com

 
Apeel Sciences creates products from natural plant extracts that allow growers to reduce reliance on pesticides, increase produce quality, and provide superior shelf life without refrigeration.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.Apeel.com
  • 819 Reddick Street
    Santa Barbara, CA USA 93103
  • Phone: 877.926.5184

Executives

Name Title Contact Details
Susan McCain
Vice President, Associate General Counsel, Intellectual Property and Risk Profile
Stephen Kaun
Senior Director, Technology Profile

Funding

Apeel Sciences raised $33M on 12/13/2016
Apeel Sciences raised $70M on 07/31/2018
Apeel Sciences raised $30M on 10/27/2020

Similar Companies

RCSB Protein Data Bank

The Protein Data Bank (PDB) was established as the 1st open access digital data resource in all of biology and medicine. It is today a leading global resource for experimental data central to scientific discovery.

Alvine Pharmaceuticals

Alvine Pharmaceuticals is a San Carlos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Intarcia

We operate with a “No Analog” mindset—continually pushing boundaries, navigating new terrain and unleashing fresh thinking. We are committed to seeking better outcomes which compels us to ask questions that have not been asked before or remain unresolved. We are driven by a desire to create meaningful impact across business, health and society to ease the burden on people living with chronic diseases. Intarcia is a rapidly emerging biotech company dedicated to redesigning the treatment, prevention and experience of chronic disease. Our cross-disciplinary teams include forward-thinking scientists and entrepreneurs collaborating in a fast-paced environment redefining the future of medicine.

Copernicus

Copernicus is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Shattuck Labs

Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck`s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company`s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina.